Used in pharmaceutical research as a selective and potent agonist for the GPR40 receptor, (R)-BDP9066 is being investigated for its potential in enhancing glucose-dependent insulin secretion, making it a candidate for the treatment of type 2 diabetes. Its high selectivity allows for targeted activation of GPR40 without significant off-target effects, supporting its use in preclinical studies to understand metabolic pathways and beta-cell function. The compound has shown improved pharmacokinetic properties in animal models, contributing to sustained glucose control and reduced hyperglycemia.